Great Point Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Great Point Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-435,000	Closed	-$28.3M	–	48
2020 Q3	$28.3M	Sell	435,000 -405,900	-48%	-$26.6M	2.54%	14
2020 Q2	$61.5M	Buy	840,900 +258,995	+45%	+$13.8M	4.91%	9
2020 Q1	$19.8M	Buy	+581,905	New	+$26.6M	2.07%	17
2019 Q3	–	Sell	-350,000	Closed	-$15.3M	–	47
2019 Q2	$15.3M	Buy	+350,000	New	+$19.7M	1.7%	16
2018 Q1	–	Sell	-500,192	Closed	-$13.5M	–	55
2017 Q4	$13.5M	Buy	+500,192	New	+$13.8M	2.3%	19

Other funds holding BHVN

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's BHVN Position: Q4 2020 in Review

Great Point Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2020, closing a stake of 435,000 shares — an estimated $28.3M sold.

Great Point Partners first reported a position in BHVN in Q4 2017 and held it in 5 quarters. The position peaked at $61.5M in Q2 2020. 238 funds tracked by Wall St. Rank hold BHVN as of Q4 2020.

Great Point Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2020 after selling out during the quarter.
Great Point Partners sold 435,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2020, an estimated $28.3M.
Great Point Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 5 quarters.
Great Point Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $61.5M in Q2 2020.
238 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2020.

Based on Great Point Partners's 13F filing for Q4 2020, filed 16 Feb 2021.